Antibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14685-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#14685-1-AP, RRID:AB_2158610
- Product name
- PAK4 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated PAK4 antibody (Cat. #14685-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: FC, IF, IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Proximity proteomics identifies PAK4 as a component of Afadin-Nectin junctions.
Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
PAK4 inhibition improves PD-1 blockade immunotherapy.
PAK4 suppresses TNF-induced release of endothelial microparticles in HUVECs cells.
ZEB1-Mediated Transcriptional Upregulation of circWWC3 Promotes Breast Cancer Progression through Activating Ras Signaling Pathway.
Nonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4.
Normal mammary gland development after MMTV-Cre mediated conditional PAK4 gene depletion.
Trio Haploinsufficiency Causes Neurodevelopmental Disease-Associated Deficits.
CCM2 and PAK4 act downstream of atrial natriuretic peptide signaling to promote cell spreading.
MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway.
The Cdc42 Effector Kinase PAK4 Localizes to Cell-Cell Junctions and Contributes to Establishing Cell Polarity.
Baskaran Y, Tay FP, Ng EYW, Swa CLF, Wee S, Gunaratne J, Manser E
Nature communications 2021 Sep 7;12(1):5315
Nature communications 2021 Sep 7;12(1):5315
Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A, Sierra L, Tsang SV, Kurenbekova L, Patel T, Rajapakse K, Shuck RL, Rainusso N, Landesman Y, Unger T, Coarfa C, Yustein JT
Cancer research 2021 Jan 1;81(1):199-212
Cancer research 2021 Jan 1;81(1):199-212
PAK4 inhibition improves PD-1 blockade immunotherapy.
Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A
Nature cancer 2020;1(1):46-58
Nature cancer 2020;1(1):46-58
PAK4 suppresses TNF-induced release of endothelial microparticles in HUVECs cells.
Zhang S, Yin Y, Li C, Zhao Y, Wang Q, Zhang X
Aging 2020 Jul 12;12(13):12740-12749
Aging 2020 Jul 12;12(13):12740-12749
ZEB1-Mediated Transcriptional Upregulation of circWWC3 Promotes Breast Cancer Progression through Activating Ras Signaling Pathway.
Meng L, Liu S, Liu F, Sang M, Ju Y, Fan X, Gu L, Li Z, Geng C, Sang M
Molecular therapy. Nucleic acids 2020 Aug 19;22:124-137
Molecular therapy. Nucleic acids 2020 Aug 19;22:124-137
Nonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4.
Zhang X, Fang J, Chen S, Wang W, Meng S, Liu B
Cancer medicine 2019 Sep;8(12):5716-5734
Cancer medicine 2019 Sep;8(12):5716-5734
Normal mammary gland development after MMTV-Cre mediated conditional PAK4 gene depletion.
Rabieifar P, Zhuang T, Costa TDF, Zhao M, Strömblad S
Scientific reports 2019 Oct 8;9(1):14436
Scientific reports 2019 Oct 8;9(1):14436
Trio Haploinsufficiency Causes Neurodevelopmental Disease-Associated Deficits.
Katrancha SM, Shaw JE, Zhao AY, Myers SA, Cocco AR, Jeng AT, Zhu M, Pittenger C, Greer CA, Carr SA, Xiao X, Koleske AJ
Cell reports 2019 Mar 5;26(10):2805-2817.e9
Cell reports 2019 Mar 5;26(10):2805-2817.e9
CCM2 and PAK4 act downstream of atrial natriuretic peptide signaling to promote cell spreading.
Miura K, Nojiri T, Akitake Y, Ando K, Fukuhara S, Zenitani M, Kimura T, Hino J, Miyazato M, Hosoda H, Kangawa K
The Biochemical journal 2017 May 19;474(11):1897-1918
The Biochemical journal 2017 May 19;474(11):1897-1918
MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway.
Sheng N, Tan G, You W, Chen H, Gong J, Chen D, Zhang H, Wang Z
Cancer medicine 2017 Jun;6(6):1331-1340
Cancer medicine 2017 Jun;6(6):1331-1340
The Cdc42 Effector Kinase PAK4 Localizes to Cell-Cell Junctions and Contributes to Establishing Cell Polarity.
Selamat W, Tay PL, Baskaran Y, Manser E
PloS one 2015;10(6):e0129634
PloS one 2015;10(6):e0129634
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- COLO 320 cells were subjected to SDS PAGE followed by western blot with 14685-1-AP(PAK4 antibody) at dilution of 1:800
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of Hela cells, using PAK4 antibody 14685-1-AP at 1:25 dilution and Rhodamine-labeled goat anti-rabbit IgG (red).
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human prostate cancer using 14685-1-AP(PAK4 antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human prostate cancer using 14685-1-AP(PAK4 antibody) at dilution of 1:100 (under 40x lens)
- Sample type
- tissue